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Hepatitis B X-interacting protein (HBXIP) is able to enhance migration of breast cancer cells. How-
ever, the role of HBXIP in regulation of complement-dependent cytotoxicity (CDC) in breast cancer is
not understood. Here, we report that HBXIP contributes to protecting breast cancer cells from CDC
by upregulating membrane-bound complement regulatory protein (mCRPs), including CD46, CD55
and CD59. We found that HBXIP upregulated mCRPs through activating p-ERK1/2/NF-jB. Interest-
ingly, the knockdown of CD59 was able to block the HBXIP-enhanced breast tumor growth in ani-
mal. Thus, we conclude that HBXIP upregulates CD46, CD55 and CD59 through p-ERK1/2/NF-jB
signaling to protect breast cancer from CDC.
Crown Copyright  2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction cytotoxicity (CDC) [4–6]. Increased expression of mCRPs has beenMammalian hepatitis B X-interacting protein (HBXIP) is a con-
served 18 kDa protein that was originally identiﬁed through its
interaction with hepatitis B virus X protein [1]. We previously
found that positive rates of HBXIP in primary tumor tissues and
metastatic lymph tissues were 75% (38/49) and 94% (36/38),
respectively [2]. However, HBXIP expression was not detectable
in normal breast tissues (0/11), suggesting that HBXIP is a novel
oncoprotein. Normal cells are protected from inappropriate com-
plement attack by membrane-bound complement regulatory pro-
teins (mCRPs), including CD46, CD55 and CD59, which prevent
complement activation or block the formation of the terminal cyto-
lytic membrane attack complex (MAC) [3]. It has been reported that
tumor cells also express mCRPs, which serve as an effective mech-
anism to evade immune surveillance and complement-dependentd by Elsevier B.V. on behalf of Fede
protein; mCRPs, membrane-
ent-dependent cytotoxicity;
tracellular regulatory kinase;
ng), yelihong@nankai.edu.cnidentiﬁed in several different malignancies, including colorectal,
gastric, lung, renal, hepatoma and breast cancers [7–9]. However,
the mechanism by which complement regulatory proteins are reg-
ulated in tumor cells during CDC remains unclear.
In the present study, we report that HBXIP is able to regulate
CD46, CD55 and CD59 through p-ERK1/2/NF-jB signaling to pro-
tect breast cells from complement attack. The ﬁnding provides
new insight into the mechanism of HBXIP in regulation of CDC.
2. Materials and methods
2.1. Cell culture and treatment
MCF-7 and LM-MCF-7 cells were cultured in RPMI 1640 med-
ium (Gibco, USA) [10]. The breast cancer cell line MDA-MB-231
were cultured in DMEM medium (Gibco) supplemented with 10%
fetal calf serum (Gibco), 100 U/ml penicillin, 100 U/ml streptomy-
cin and 1% glutamine streptomycin in 5% CO2 at 37 C. Cells were
plated into 6-well plates. Twenty-four hours later, the cells were
placed in serum-free medium for an additional 12 h. In brief,
MCF-7 and MDA-MB-231 cells containing overexpressed or
silenced HBXIP, were treated with 30 lM PD98059 (an inhibitor
of MEK1, Sigma, USA) for 1–4 h or 60 lM PDTC (an inhibitor of
NF-jB, Sigma) for 1, 2 h, respectively.ration of European Biochemical society. All rights reserved.
Fig. 1. HBXIP decreases the sensitivity of breast cancer cells to CDC via upregulating mCRPs. (A) The effect of HBXIP on the response of MCF-7 cells to CDC was examined by
Trypan blue absorbance assay in stable HBXIP (or HBXIP RNAi)-transfection system. The heated-normal human serum (h-NHS) was served as negative control. (B) The 25 ng/
ml antibodies of mCRPs, such as rabbit anti-CD46, rabbit anti-CD55 or rabbit anti-CD59 were added into 2 ml medium of MCF-7-pCMV cells or MCF-7-HBXIP cells for 30 min,
respectively. Then, the effect of HBXIP on the response of MCF-7 cells to CDC was examined by trypan blue absorbance assay in the cells. (C) The effect of HBXIP-
overexpression on activation of CD46, CD55 and CD59 was examined by luciferase reporter gene assay in MCF-7 or MDA-MB-231 (231) cells. ⁄⁄P < 0.001 vs control, Student’s
t-test. (D and E) The expression levels of mCRPs were examined by qRT-PCR and western blot analysis in breast cell lines, respectively.
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The extent of complement-mediated tumor cell death was
determined by Trypan blue absorbance assay, according to the
method as previously described [11].2.3. Tumor formation in nude mice
The tumorigenicity of MCF-7-pCMV stable cells (pretreated
with psi-random), MCF-7-HBXIP stable cells (pretreated with psi-
random) [12] or MCF-7-HBXIP stable cells (pretreated with
Fig. 2. HBXIP activates NF-jB signaling through increasing p-ERK1/2. (A) The phosphate levels of p-ERK1/2, p-JNK, or p-p38 were tested by western blot analysis in MCF-7-
HBXIP cells relative to MCF-7 or MCF-7-pCMV cells (B) Promoter activities of CD46, CD55 and CD59 was examined by luciferase reporter gene assay in transiently HBXIP-
transfected MCF-7 cells after treatment with 30 lM PD98059 for 120 min. ⁄⁄P < 0.001, vs control, Student’s t-test. (C) The protein expression levels of mCRPs were determined
by western blot in MCF-7-HBXIP cells after treatment with 30 lM PD98059 in time course. (D) The phosphate level of p-IjBa was test with the transfection of HBXIP and a
treatment of 60 lM PDTC by western blot analysis. (E) NF-jB-p65 nuclear translocation mediated by HBXIP was examined with 30 lM PD98059 by immunoﬂuorescence
staining and nuclear western blot in MCF-7 cells. Bar means 50 lm.
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(0.2 ml) with 2  106 cells were injected subcutaneously into 4-
week-old nude mice (n = 6 each group). All studies were approved
by the Animal Care Committee of Nankai University.
2.4. Statistical analysis
Statistical analysis was performed using Sigma Plot 2001 (Sy-
stat Software Inc., Richmond, CA). Statistical signiﬁcance was as-
sessed by comparing mean values (±S.D.) using Student’s t-test
(⁄P < 0.05, ⁄⁄P < 0.001). P < 0.05 was considered as signiﬁcant.
3. Results
3.1. HBXIP decreases the sensitivity of breast cancer cells to CDC via
upregulating mCRPs
Recently, we reported that HBXIP was involved in breast cancer
cell migration [2]. We observed the effect of HBXIP on CDC in
breast cancer cells because HBXIP is an important oncoprotein. In
this study, our data showed that HBXIP decreased the sensitivityof the cells to CDC in MCF-7 cells (Fig. 1A), suggesting that HBXIP
is involved in CDC. Fig. 1B showed that the blocking of mCRPs
using the antibodies of CD46, CD55 and CD59, respectively, was
able to rescue the HBXIP-induced sensitivity of the cells to CDC
in MCF-7 cells, supporting that CD46, CD55 and CD59 were in-
volved in the HBXIP-induced CDC. To further explore the relation-
ship between HBXIP and mCRPs, we generated several stable cell
lines with overexpression or knockdown of HBXIP, called MCF-7-
HBXIP (overexpression of HBXIP), MCF-7-psi-HBXIP (knockdown
of HBXIP), MDA-MB-231-HBXIP (overexpression of HBXIP) and
MDA-MB-231-psi-HBXIP (knockdown of HBXIP), respectively.
Our results showed that the relative luciferase activities of CD46,
CD55 and CD59 were signiﬁcantly higher in HBXIP-transfected
MCF-7 and MDA-MB-231 cells than that in control cells
(⁄P < 0.05, ⁄⁄P < 0.001 vs MCF-7 or MDA-MB-231, Student’s t-test)
(Fig. 1C). Furthermore, western blot and qRT-PCR analysis showed
that the overexpression or knockdown of HBXIP was able to regu-
late the expression of CD46, CD55 and CD59 in MCF-7 and MDA-
MB-231 (Fig. 1D, E, S1A and S1B). All above data strongly suggest
that HBXIP is able to upregulate the expression of CD46, CD55
and CD59.
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involving increasing p-ERK1/2
It has been reported that ERK contributes to CDC resistance in a
human immortalized myelogenous leukemia line [13] and the CDC
resistance of breast cancer cells is associated with aberrant activa-
tion of MAPK [14]. Thus, we supposed that MAPK may be involved
in the HBXIP-mediated upregulation of mCRPs. Interestingly, we
found that the level of p-ERK1/2, but not p-JNK or p-p38, was in-
creased in MCF-7-HBXIP cells (Fig. 2A). Our data showed that the
treatment with 30 lM PD98059 (an inhibitor of MEK) abolished
the increased promoter activities and protein expression of CD46,
CD55 and CD59 mediated by HBXIP in MCF-7 cells (⁄⁄P < 0.001,
vs control, Student’s t-test, Fig. 2B and C). The above data suggest
that HBXIP is able to upregulate mCRPs through activating ERK1/
2. Moreover, we found that PDTC (an inhibitor of NF-jB) failed to
abolish the increased level of p-ERK1/2 mediated by overexpress-
ing HBXIP in MCF-7 cells. However, PD98059 was able to abolish
the increased level of p-IjBa in above cells (Fig. 2D). Immuno-ﬂuo-
rescence staining revealed that the treatment with 30 lM
PD98059 attenuated the nuclear translocation of the NF-jB-p65Fig. 3. The activation NF-jB is responsible for the upregulation of CD46, CD55 and CD59
by HBXIP was measured by luciferase reporter gene assay in transiently HBXIP-transfec
120 min. ⁄P < 0.05; ⁄⁄P < 0.001, vs. controls, Student’s t-test. (B) Expression levels of CD46
MB-231-HBXIP (231-HBXIP) cells after treatment with 60 lM PDTC in time course. (C) T
HBXIP and MDA-MB-231-HBXIP (231-HBXIP) cells were transfected by NF-jB-p65 siRNsubunit in transient-HBXIP transfected MCF-7 cells. Similarly, we
also found that the similar results in the nucleus proteins by wes-
tern blot analysis (Fig. 2E). Therefore, these data show that the acti-
vation of NF-jB mediated by HBXIP is in a p-ERK1/2 signaling-
dependent manner in breast cancer cells.
To validate the further mechanism of upregulation of CD46,
CD55 and CD59, we examined the effect of NF-jB on these upregu-
lations. Luciferase reporter gene assay showed that the treatment
with PDTC abolished the increased promoter activities of CD46,
CD55 and CD59 when HBXIP was overexpressed by transient trans-
fection with pCMV-HBXIP plasmid in MCF-7 and MDA-MB-231
cells (⁄P < 0.05; ⁄⁄P < 0.001, vs controls, Student’s t-test, Fig. 3A).
Western blot analysis showed that PDTC was able to abolish the
upregulation of CD46, CD55 and CD59 in MCF-7-HBXIP and
MDA-MB-231-HBXIP cells in a time-dependent manner (Fig. 3B).
In addition, the NF-jB-p65 siRNA resulted in the downregulation
of mCRPs in MCF-7-HBXIP cells and MDA-MB-231-HBXIP cells
(Fig. 3C). These data suggest that NF-jB signaling pathway is
responsible for the upregulation of CD46, CD55 and CD59 medi-
ated by HBXIP in breast cancer cells.. (A) The effect of NF-jB on enhancement of promoter activities of mCRPs mediated
ted MCF-7 cells and MDA-MB-231 (231) cells after treatment with 60 lM PDTC for
, CD55 and CD59 were detected by western blot analysis in MCF-7-HBXIP and MDA-
he expression level of NF-jB-p65 was measured by western blot analysis. MCF-7-
A.
Fig. 4. p-ERK1/2 and NF-jB are involved in CDC mediated by HBXIP. (A) The effect of p-ERK1/2 or NF-jB on response of MCF-7-HBXIP cells to CDC was examined by trypan
blue absorbance assay in different dilutions of normal human serum after treatment with 30 lMPD98059 or 60 lM PDTC. Meanwhile, the downregulation of CD46, CD55 and
CD59 were examined by western blot analysis. ⁄⁄P < 0.001, Student’s t-test. (B) Tumor size was measured every 5 days using a vernier caliper. Each bar shows the mean ± S.D.
(n = 6) (left panel). The tumors from xenograft mouse models were shown (right panel). ⁄P < 0.05, Student’s t-test.
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In function, we found that the inhibition of ERK1/2 and NF-jB
was able to sensitize the MCF-7-HBXIP cells to CDC (Fig. 4A)
(⁄⁄P < 0.001, vs control, Student’s t-test). We then examined the ef-
fect of CD59 on tumor growth in HBXIP-overexpression MCF-7
breast cancer cells in mice using psi-CD59. Interestingly, the sup-
pression of tumor growth was observed in nude mice injected by
MCF-7-HBXIP cells pretreated with psi-CD59 (⁄P < 0.05, Student’s
t-test, Fig. 4B), suggesting that HBXIP enhances cell growth in mice
is in a CD59-dependent manner. The knockdown efﬁciency of CD59
by psi-CD59 was detected by western blot in MCF-7 cell (Fig. S1C).
Thus, we conclude that HBXIP contributes to the protection of
breast cancer cells from CDC through upregulation of mCRPs
involving a cascade signal of p-ERK1/2/ NF-jB.
4. Discussion
Recently, we have reported that HBXIP is involved in the prolif-
eration and migration of breast cancer cells [2]. In this study, we
investigated the role of HBXIP in regulation of mCRPs in breast can-
cer cells. We found that HBXIP was inversely associated with the
sensitivity of the cells to CDC in MCF-7 cells (Fig. 1). mCRPs play
an important role in the immune evasion strategy of tumors by
inhibiting complement cascade activation [5]. Interestingly, HBXIP
expression is positively correlated with the expression of mCRPs in
breast cancer cells. Then, we further demonstrated that HBXIP was
able to upregulate the expression of CD46, CD55 and CD59 at the
levels of promoter activity, mRNA expression and protein expres-
sion in breast cancer cells.
Next, we focused on the investigation of mechanism of upregu-
lation of mCRPs mediated by HBXIP. According to the report that
the survival capability of breast cancer cells is associated with
aberrant activation of MAPK [14] and ERK contributes to CDC resis-
tance in a human immortalized myelogenous leukemia line [13],we supposed that MAPK may be involved in the HBXIP-mediated
upregulation of mCRPs. Then, we showed that HBXIP increased
the phosphorylation of ERK1/2, but not p-JNK or p-p38, in
MCF-7-HBXIP cells. Indeed, it was conﬁrmed that the increase of
p-ERK1/2 level was responsible for upregulating mCRPs (Fig. 2).
Because we previously reported that HBXIP activates NF-jB in
hepatoma cells [12], the relationship between p-ERK1/2 and NF-
jB in HBXIP-mediated upregulation of mCRPs was required to be
identiﬁed. Interestingly, we found that the activation of NF-jB
mediated by HBXIP is in a p-ERK1/2 signaling-dependent manner
in breast cancer cells. These data are consistent with a report
showing that NF-jB is a downstream effector of p-ERK1/2 [15].
We further demonstrated that NF-jB was involved in HBXIP-med-
iated upregulation of mCRPs in breast cancer cells.
Consequently, increased complement resistance conferred by
these mCRPs has been proposed as a mechanism that facilitates tu-
mor survival or survival of metastasizing tumor cells in the circu-
lation [15–17]. According to our above observations, we need to
show all the factors involving the upregulation of mCRPs, such as
p-ERK1/2, NF-jB and CD59, are responsible for CDC in breast
cancer cells. Our ﬁnding suggests that the activation of ERK1/2
and NF-jB plays a critical role in regulation of mCRPs involving
CDC, which is consistent with the previous reports [13,18].
Taken together, we summarize a model that HBXIP is a novel
regulator for CD46, CD55 and CD59, involving ERK1/2/NF-jB sig-
naling, which contributes to protecting the cells from complement
attack (Fig. S2). Our data provide new insights into the mechanism
of regulation of mCRPs in breast cancer cells.Acknowledgments
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